Alnylam Pharmaceuticals
ALNY
#550
Rank
โ‚ฌ37.91 B
Marketcap
286,99ย โ‚ฌ
Share price
0.31%
Change (1 day)
7.12%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): โ‚ฌ93.93 Million

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚ฌ3.21 Billion. In 2024 the company made an earning of -โ‚ฌ0.2 Billion, an increase over its 2023 earnings that were of -โ‚ฌ0.27 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) โ‚ฌ93.93 M-147.13%
2024 -โ‚ฌ0.2 Billion-24.59%
2023 -โ‚ฌ0.27 Billion-67.84%
2022 -โ‚ฌ0.83 Billion36.93%
2021 -โ‚ฌ0.61 Billion-8.04%
2020 -โ‚ฌ0.66 Billion-15.66%
2019 -โ‚ฌ0.78 Billion12.23%
2018 -โ‚ฌ0.69 Billion62.91%
2017 -โ‚ฌ0.43 Billion17.78%
2016 -โ‚ฌ0.36 Billion43.44%
2015 -โ‚ฌ0.26 Billion60.69%
2014 -โ‚ฌ0.16 Billion98.2%
2013 -โ‚ฌ78.66 Million
2011 -โ‚ฌ46.4 Million27.48%
2010 -โ‚ฌ36.4 Million-10.92%
2009 -โ‚ฌ40.86 Million95.77%
2008 -โ‚ฌ20.87 Million
2006 -โ‚ฌ33.43 Million-9.13%
2005 -โ‚ฌ36.8 Million34.74%
2004 -โ‚ฌ27.31 Million36.79%
2003 -โ‚ฌ19.97 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚ฌ13.89 B 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚ฌ7.70 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚ฌ4.35 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚ฌ0.22 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚ฌ40.14 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚ฌ0.14 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚ฌ1.49 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚ฌ0.11 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA